HSP90B1 and neoplasm: Dr. Podack’s inspiring work on the development of an anti-tumor gp96 vaccine twenty years ago was successfully translated into numerous pre-clinical and clinical studies, including Phase 1b/2 clinical trial (NCT02439450) for patients with non-small cell lung cancer (NSCLC).